What is the first‑line medication for an adult with depression or bipolar disorder experiencing suicidal ideation?

Best Medication for Suicidal Ideation in Adults with Depression or Bipolar Disorder

For adults with bipolar disorder and suicidal ideation, lithium is the first-line medication due to its proven suicide prevention effects; for adults with major depressive disorder and acute suicidal ideation, ketamine infusion provides rapid reduction in suicidal thoughts within 24 hours, though lithium remains the gold standard for long-term suicide prevention in mood disorders.

Algorithmic Approach by Diagnosis

For Bipolar Disorder with Suicidal Ideation

Primary recommendation: Lithium

• Lithium demonstrates the strongest evidence for reducing suicide risk in bipolar disorder, with effects that extend beyond mood stabilization 1, 2, 3
• Recent data shows lithium reduces suicidal ideation by 4.78-fold and suicide attempts by 6.54-fold compared to treatment without lithium 4
• This antisuicidal effect appears independent of its mood-stabilizing properties 5
• Lithium is FDA-approved for bipolar disorder in patients age 12 and older 6

Alternative for treatment-resistant cases: Clozapine

• Reserved specifically for schizophrenia or schizoaffective disorder with suicidal behavior 1, 2
• FDA-approved for "reducing the risk of recurrent suicidal behavior" but primarily studied in psychotic disorders, not mood disorders 7
• Not first-line due to agranulocytosis risk and mandatory monitoring requirements 1

For Major Depressive Disorder with Acute Suicidal Ideation

For immediate crisis (within 24 hours to 1 week):

• Ketamine infusion (0.5 mg/kg single dose) provides rapid antisuicidal effects 1, 8, 2
• 55% of patients report no suicidal ideation at 24 hours; 60% at 7 days 1
• Benefits begin within 24 hours and persist for at least 1 week, sometimes up to 6 weeks 1
• The 2022 VA/DoD guideline supports ketamine as adjunctive treatment for short-term reduction in suicidal ideation 8
• Critical limitation: Lacks long-term efficacy data and is not approved for preventing suicide attempts 8, 2

For maintenance after acute stabilization:

• Transition to lithium for long-term suicide prevention 7, 3, 4
• Lithium reduces both suicidal ideation (4.78-fold) and attempts (6.54-fold) in MDD patients during long-term treatment 4
• This represents the most robust evidence for sustained antisuicidal effects 5

Evidence Hierarchy and Nuances

Strongest Evidence (Guideline-Level)

The 2019 VA/DoD guideline 1 and updated 2024 version 2 provide the most authoritative recommendations:

• Ketamine: Weak recommendation FOR short-term reduction in suicidal ideation in MDD 2
• Lithium: Insufficient evidence rating upgraded based on newer data, though guidelines remain cautious 2
• Clozapine: Weak recommendation FOR reducing suicide attempts in schizophrenia/schizoaffective disorder 2

Critical Distinctions

Ketamine vs. Esketamine:

• Intranasal esketamine (FDA-approved for treatment-resistant depression) shows similar rapid effects 8
• Requires 2-hour post-treatment monitoring and REMS certification 8
• Neither ketamine nor esketamine has established efficacy for preventing suicide attempts—only for reducing ideation 2, 9

Age-Specific Considerations:

• Psychotropic medications show time-dependent reduction in suicidal ideation in adults ≥25 years 9
• This effect is NOT observed in patients <25 years 9
• Antidepressants carry FDA warnings about increased suicidal risk in children/adolescents during the first 10-14 days 10

Common Pitfalls to Avoid

1. Using antidepressants as monotherapy in bipolar disorder: This can destabilize mood and trigger manic episodes, potentially worsening suicidality 6

2. Relying solely on antidepressants for suicidal ideation: Standard antidepressants do not provide rapid relief of suicidal thoughts 7. Their antisuicidal effects are primarily mediated through improvement in depressive symptoms, not direct effects on suicide diathesis 5

3. Expecting ketamine to prevent suicide attempts: While ketamine rapidly reduces suicidal ideation, there is insufficient evidence it prevents actual suicide attempts 2, 9

4. Discontinuing lithium prematurely: One study showed high relapse rates even in adolescents stabilized on lithium when it was discontinued 6, emphasizing the need for maintenance treatment

5. Overlooking the 10-14 day risk window: When initiating antidepressants, suicidal behavior risk exists during the first 10-14 days, requiring careful monitoring 10

Practical Implementation

Acute presentation (emergency department/inpatient):

• Ketamine infusion for immediate suicidal ideation reduction in MDD
• Initiate lithium simultaneously for long-term prevention
• Consider atypical antipsychotics as adjuncts if psychotic features present

Outpatient management:

• Lithium as first-line for both bipolar disorder and recurrent MDD with suicidal ideation
• Monitor lithium levels and renal/thyroid function
• Combine with cognitive behavioral therapy focused on suicide prevention 1, 2

Treatment-resistant cases:

• Consider clozapine only for schizophrenia/schizoaffective disorder with established diagnosis 1, 6
• Combination mood stabilizers may be necessary in bipolar disorder 6

The evidence strongly supports lithium as the medication with the most robust long-term antisuicidal effects across mood disorders 5, 4, while ketamine serves as a bridge therapy for acute crises in MDD 1, 8, 2.